The DOI matches its Crossref record; 298 of the 298 references it cites were found in a registry or an index.
Exploiting replicative stress to treat cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Maternal Embryonic Leucine Zipper Kinase (MELK) Reduces Replication Stress in Glioblastoma Cells
Kığ, C., Beullens, M., Beke, L., Eynde, A. V., Linders, J. T., Brehmer, D., & Bollen, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.471433 · Cited by 41
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171737a0 · Cited by 13,584
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Association of reactive oxygen species levels and radioresistance in cancer stem cells
Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Dorie, M. J., Kulp, A. N., Qian, D., Lam, J. S., Ailles, L. E., Wong, M., et al. (2009) · Nature · doi:10.1038/nature07733 · Cited by 2,555
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Genomic instability — an evolving hallmark of cancer
Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397
Genetical Implications of the Structure of Deoxyribonucleic Acid
WATSON, J. D., & CRICK, F. H. C. (1953) · Nature · doi:10.1038/171964b0 · Cited by 2,197
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Sauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., Becker, H., Raab, H.-R., Villanueva, M.-T., Witzigmann, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1836 · Cited by 2,095
Causes and consequences of replication stress
Zeman, M. K., & Cimprich, K. A. (2014) · Nature Cell Biology · doi:10.1038/ncb2897 · Cited by 2,079
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798
The history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765
OPA1 Controls Apoptotic Cristae Remodeling Independently from Mitochondrial Fusion
Frezza, C., Cipolat, S., Martins de Brito, O., Micaroni, M., Beznoussenko, G. V., Rudka, T., Bartoli, D., Polishuck, R. S., Danial, N. N., De Strooper, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.025 · Cited by 1,673
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA
Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/369574a0 · Cited by 1,655
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?
Sabharwal, S. S., & Schumacker, P. T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3803 · Cited by 1,622
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Genetical Implications of the Structure of Deoxyribonucleic Acid
Watson, J. D., & Crick, F. H. C. (2017) · Klassische Texte der Wissenschaft · doi:10.1007/978-3-662-47150-0_5 · Cited by 1,297
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
The antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Tackling the cancer stem cells — what challenges do they pose?
Pattabiraman, D. R., & Weinberg, R. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4253 · Cited by 990
Balancing repair and tolerance of DNA damage caused by alkylating agents
Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3185 · Cited by 947
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
ATR prohibits replication catastrophe by preventing global exhaustion of RPA
Toledo, L. I., Altmeyer, M., Rask, M.-B., Lukas, C., Larsen, D. H., Povlsen, L. K., Bekker-Jensen, S., Mailand, N., Bartek, J., & Lukas, J. (2013) · Cell · doi:10.1016/j.cell.2013.10.043 · Cited by 911
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., & Nakamura, Y. (2000) · Nature · doi:10.1038/35003506 · Cited by 904
Replication stress links structural and numerical cancer chromosomal instability
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E., et al. (2013) · Nature · doi:10.1038/nature11935 · Cited by 878
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
Nucleotide deficiency promotes genomic instability in early stages of cancer development
Bester, A. C., Roniger, M., Oren, Y. S., Im, M. M., Sarni, D., Chaoat, M., Bensimon, A., Zamir, G., Shewach, D. S., & Kerem, B. (2011) · Cell · doi:10.1016/j.cell.2011.03.044 · Cited by 858
Jackson, D. A., & Pombo, A. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.6.1285 · Cited by 841
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Targeting IAP proteins for therapeutic intervention in cancer
Fulda, S., & Vucic, D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3627 · Cited by 837
Petermann, E., Orta, M. L., Issaeva, N., Schultz, N., & Helleday, T. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.021 · Cited by 828
Maintaining genome stability at the replication fork
Branzei, D., & Foiani, M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2852 · Cited by 786
Cipolat, S., Rudka, T., Hartmann, D., Costa, V., Serneels, L., Craessaerts, K., Metzger, K., Frezza, C., Annaert, W., D'Adamio, L., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.021 · Cited by 741
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 719
The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair
Sørensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuåsen, R. G., Lundin, C., Bartek, J., & Helleday, T. (2005) · Nature Cell Biology · doi:10.1038/ncb1212 · Cited by 666
Self-citationY-family DNA polymerases and their role in tolerance of cellular DNA damage
Sale, J. E., Lehmann, A. R., & Woodgate, R. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3289 · Cited by 665
Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair
Li, R., Waga, S., Hannon, G. J., Beach, D., & Stillman, B. (1994) · Nature · doi:10.1038/371534a0 · Cited by 643
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633
Alkylating DNA damage stimulates a regulated form of necrotic cell death
Zong, W.-X., Ditsworth, D., Bauer, D. E., Wang, Z.-Q., & Thompson, C. B. (2004) · Genes & Development · doi:10.1101/gad.1199904 · Cited by 618
Lange, S. S., Takata, K.-I., & Wood, R. D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2998 · Cited by 615
Dynamic Molecular Combing: Stretching the Whole Human Genome for High-Resolution Studies
Michalet, X., Ekong, R., Fougerousse, F., Rousseaux, S., Schurra, C., Hornigold, N., Slegtenhorst, M. V., Wolfe, J., Povey, S., Beckmann, J. S., et al. (1997) · Science · doi:10.1126/science.277.5331.1518 · Cited by 611
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2716 · Cited by 609
Dormant origins licensed by excess Mcm2–7 are required for human cells to survive replicative stress
Ge, X. Q., Jackson, D. A., & Blow, J. J. (2007) · Genes & Development · doi:10.1101/gad.457807 · Cited by 604
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Paulovich, A. G., & Hartwell, L. H. (1995) · Cell · doi:10.1016/0092-8674(95)90481-6 · Cited by 588
Mechanisms Governing Metastatic Dormancy and Reactivation
Giancotti, F. G. (2013) · Cell · doi:10.1016/j.cell.2013.10.029 · Cited by 586
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Helmrich, A., Ballarino, M., & Tora, L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.013 · Cited by 574
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
Sørensen, C. S., Syljuåsen, R. G., Falck, J., Schroeder, T., Rönnstrand, L., Khanna, K. K., Zhou, B.-B., Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00048-5 · Cited by 559
Self-citationPaulsen, R. D., Soni, D. V., Wollman, R., Hahn, A. T., Yee, M.-C., Guan, A., Hesley, J. A., Miller, S. C., Cromwell, E. F., Solow-Cordero, D. E., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.021 · Cited by 555
Syljuåsen, R. G., Sørensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., Sehested, M., Lukas, J., & Bartek, J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3553-3562.2005 · Cited by 550
Self-citationInteraction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
Gad, H., Koolmeister, T., Jemth, A.-S., Eshtad, S., Jacques, S. A., Ström, C. E., Svensson, L. M., Schultz, N., Lundbäck, T., Einarsdottir, B. O., et al. (2014) · Nature · doi:10.1038/nature13181 · Cited by 514
Nogueira, V., & Hay, N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1424 · Cited by 514
Heinemann, V., Hertel, L. W., Grindey, G. B., & Plunkett, W. K. (1988) · PubMed · Cited by 504
Topoisomerase I poisoning results in PARP-mediated replication fork reversal
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., & Lopes, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2258 · Cited by 499
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498
Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2
Reinhardt, H. C., & Yaffe, M. B. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.018 · Cited by 497
A census of amplified and overexpressed human cancer genes
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R., & Cooper, C. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2771 · Cited by 482
Reijns, M. A. M., Rabe, B., Rigby, R. E., Mill, P., Astell, K. R., Lettice, L. A., Boyle, S., Leitch, A., Keighren, M., Kilanowski, F., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.011 · Cited by 466
Break-Induced Replication Repair of Damaged Forks Induces Genomic Duplications in Human Cells
Costantino, L., Sotiriou, S. K., Rantala, J. K., Magin, S., Mladenov, E., Helleday, T., Haber, J. E., Iliakis, G., Kallioniemi, O. P., & Halazonetis, T. D. (2014) · Science · doi:10.1126/science.1243211 · Cited by 461
Gilson, E., & Géli, V. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2259 · Cited by 457
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Burrell, R. A., McClelland, S. E., Endesfelder, D., Groth, P., Weller, M.-C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S. M., Gronroos, E., et al. (2013) · Nature · doi:10.1038/nature12369 · Cited by 451
Identification of Early Replicating Fragile Sites that Contribute to Genome Instability
Barlow, J. H., Faryabi, R. B., Callén, E., Wong, N., Malhowski, A., Chen, H. T., Gutierrez-Cruz, G., Sun, H.-W., McKinnon, P., Wright, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.006 · Cited by 444
Analysis of protein dynamics at active, stalled, and collapsed replication forks
Sirbu, B. M., Couch, F. B., Feigerle, J. T., Bhaskara, S., Hiebert, S. W., & Cortez, D. (2011) · Genes & Development · doi:10.1101/gad.2053211 · Cited by 440
A forward chemical genetic screen reveals an inhibitor of the Mre11–Rad50–Nbs1 complex
Dupré, A., Boyer-Chatenet, L., Sattler, R. M., Modi, A. P., Lee, J.-H., Nicolette, M. L., Kopelovich, L., Jasin, M., Baer, R., Paull, T. T., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.63 · Cited by 414
ATR phosphorylates SMARCAL1 to prevent replication fork collapse
Couch, F. B., Bansbach, C. E., Driscoll, R., Luzwick, J. W., Glick, G. G., Bétous, R., Carroll, C. M., Jung, S. Y., Qin, J., Cimprich, K. A., et al. (2013) · Genes & Development · doi:10.1101/gad.214080.113 · Cited by 406
Gemcitabine: preclinical pharmacology and mechanisms of action.
Plunkett, W. K., Huang, P., Searcy, C. E., & Gandhi, V. V. (1996) · PubMed · Cited by 396
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Huber, K. V. M., Salah, E., Radic, B., Gridling, M., Elkins, J. M., Stukalov, A., Jemth, A.-S., Göktürk, C., Sanjiv, K., Strömberg, K., et al. (2014) · Nature · doi:10.1038/nature13194 · Cited by 395
The DNA damage-dependent intra–S phase checkpoint is regulated by parallel pathways
Falck, J., Petrini, J. H. J., Williams, B. R., Lukas, J., & Bartek, J. (2002) · Nature Genetics · doi:10.1038/ng845 · Cited by 392
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Epigenetic Resensitization to Platinum in Ovarian Cancer
Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3909 · Cited by 390
PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints
Lu, X., Nannenga, B., & Donehower, L. A. (2005) · Genes & Development · doi:10.1101/gad.1291305 · Cited by 389
Repairing DNA-methylation damage
Sedgwick, B. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1312 · Cited by 388
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors
Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montaña, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2189 · Cited by 381
Martínez, P., Thanasoula, M., Muñoz, P., Liao, C., Tejera, A., McNees, C., Flores, J. M., Fernández-Capetillo, O., Tarsounas, M., & Blasco, M. A. (2009) · Genes & Development · doi:10.1101/gad.543509 · Cited by 370
Fokas, E., Prevo, R., Pollard, J. R., Reaper, P. M., Charlton, P. A., Cornelissen, B., Vallis, K. A., Hammond, E. M., Olcina, M. M., Gillies McKenna, W., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.181 · Cited by 369
Woodward, A. M., Göhler, T., Luciani, M. G., Oehlmann, M., Ge, X., Gartner, A., Jackson, D. A., & Blow, J. J. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200602108 · Cited by 369
Alabert, C., Bukowski-Wills, J.-C., Lee, S.-B., Kustatscher, G., Nakamura, K., de Lima Alves, F., Menard, P., Mejlvang, J., Rappsilber, J., & Groth, A. (2014) · Nature Cell Biology · doi:10.1038/ncb2918 · Cited by 353
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 346
Myelodysplastic syndromes: the complexity of stem-cell diseases
Corey, S. J., Minden, M. D., Barber, D. L., Kantarjian, H., Wang, J. C. Y., & Schimmer, A. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2047 · Cited by 342
Pathways of mammalian replication fork restart
Petermann, E., & Helleday, T. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2974 · Cited by 340
A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging
Murga, M., Bunting, S., Montaña, M. F., Soria, R., Mulero, F., Cañamero, M., Lee, Y., McKinnon, P. J., Nussenzweig, A., & Fernandez-Capetillo, O. (2009) · Nature Genetics · doi:10.1038/ng.420 · Cited by 340
RNAi screening comes of age: improved techniques and complementary approaches
Mohr, S. E., Smith, J. A., Shamu, C. E., Neumüller, R. A., & Perrimon, N. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3860 · Cited by 332
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
Repriming of DNA synthesis at stalled replication forks by human PrimPol
Mourón, S., Rodriguez-Acebes, S., Martínez-Jiménez, M. I., García-Gómez, S., Chocrón, S., Blanco, L., & Méndez, J. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2719 · Cited by 323
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
The Dbf4–Cdc7 kinase promotes S phase by alleviating an inhibitory activity in Mcm4
Sheu, Y.-J., & Stillman, B. (2010) · Nature · doi:10.1038/nature08647 · Cited by 311
Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine
van Loon, B., Markkanen, E., & Hübscher, U. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.004 · Cited by 309
Chk1 promotes replication fork progression by controlling replication initiation
Petermann, E., Woodcock, M., & Helleday, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005031107 · Cited by 308
Beck, H., Nähse-Kumpf, V., Larsen, M. S. Y., O'Hanlon, K. A., Patzke, S., Holmberg, C., Mejlvang, J., Groth, A., Nielsen, O., Syljuåsen, R. G., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00412-12 · Cited by 306
Self-citationMany faces of DAMPs in cancer therapy
Krysko, O., Løve Aaes, T., Bachert, C., Vandenabeele, P., & Krysko, D. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.156 · Cited by 296
Senescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295
Mir, S. E., De Witt Hamer, P. C., Krawczyk, P. M., Balaj, L., Claes, A., Niers, J. M., Van Tilborg, A. A. G., Zwinderman, A. H., Geerts, D., Kaspers, G. J. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.011 · Cited by 294
Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Lin, J. J., Milhollen, M. A., Smith, P. G., Narayanan, U., & Dutta, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2062 · Cited by 292
PrimPol Bypasses UV Photoproducts during Eukaryotic Chromosomal DNA Replication
Bianchi, J., Rudd, S. G., Jozwiakowski, S. K., Bailey, L. J., Soura, V., Taylor, E., Stevanovic, I., Green, A. J., Stracker, T. H., Lindsay, H. D., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.035 · Cited by 291
The histone H4 Lys 20 methyltransferase PR-Set7 regulates replication origins in mammalian cells
Tardat, M., Brustel, J., Kirsh, O., Lefevbre, C., Callanan, M., Sardet, C., & Julien, E. (2010) · Nature Cell Biology · doi:10.1038/ncb2113 · Cited by 289
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Coiras, M., López-Huertas, M. R., Pérez-Olmeda, M., & Alcamí, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2223 · Cited by 288
CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?
Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2251 · Cited by 288
Abbas, T., Shibata, E., Park, J., Jha, S., Karnani, N., & Dutta, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.014 · Cited by 280
DNA replication stress, genome instability and aging
Burhans, W. C., & Weinberger, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1059 · Cited by 279
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Wee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein.
Cimprich, K. A., Shin, T. B., Keith, C. T., & Schreiber, S. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2850 · Cited by 273
A Preclinical Evaluation of Minnelide as a Therapeutic Agent Against Pancreatic Cancer
Chugh, R., Sangwan, V., Patil, S. P., Dudeja, V., Dawra, R. K., Banerjee, S., Schumacher, R. J., Blazar, B. R., Georg, G. I., Vickers, S. M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004334 · Cited by 268
Transcription-replication encounters, consequences and genomic instability
Helmrich, A., Ballarino, M., Nudler, E., & Tora, L. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2543 · Cited by 265
Donati, G., Peddigari, S., Mercer, C. A., & Thomas, G. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.045 · Cited by 262
CDC6: from DNA replication to cell cycle checkpoints and oncogenesis
Borlado, L. R., & Méndez, J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm268 · Cited by 262
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Maréchal, A., Li, J.-M., Ji, X. Y., Wu, C.-S., Yazinski, S. A., Nguyen, H. D., Liu, S., Jiménez, A. E., Jin, J., & Zou, L. (2014) · Molecular Cell · doi:10.1016/j.molcel.2013.11.002 · Cited by 249
Nucleoside analogs: molecular mechanisms signaling cell death
Ewald, B., Sampath, D., & Plunkett, W. (2008) · Oncogene · doi:10.1038/onc.2008.316 · Cited by 247
Sirbu, B. M., McDonald, W. H., Dungrawala, H., Badu-Nkansah, A., Kavanaugh, G. M., Chen, Y., Tabb, D. L., & Cortez, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511337 · Cited by 244
Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., & Brunner, T. B. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21093 · Cited by 241
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., & Workman, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 239
Reinhardt, H. C., Hasskamp, P., Schmedding, I., Morandell, S., van Vugt, M. A. T. M., Wang, X., Linding, R., Ong, S.-E., Weaver, D., Carr, S. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.018 · Cited by 238
A ribonucleotide reductase gene is a transcriptional target of p53 and p73
Nakano, K., Bálint, É., Ashcroft, M., & Vousden, K. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203774 · Cited by 233
Identification of Specific Inhibitors of Human RAD51 Recombinase Using High-Throughput Screening
Huang, F., Motlekar, N. A., Burgwin, C. M., Napper, A. D., Diamond, S. L., & Mazin, A. V. (2011) · ACS Chemical Biology · doi:10.1021/cb100428c · Cited by 231
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
Self-citationAapro, M. S., Martin, C., & Hatty, S. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199803000-00001 · Cited by 228
Replication licensing and cancer — a fatal entanglement?
Blow, J. J., & Gillespie, P. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2500 · Cited by 228
Visualization of Altered Replication Dynamics after DNA Damage in Human Cells
Merrick, C. J., Jackson, D., & Diffley, J. F. X. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400022200 · Cited by 228
The histone methyltransferase SET8 is required for S-phase progression
Jørgensen, S., Elvers, I., Trelle, M. B., Menzel, T., Eskildsen, M., Jensen, O. N., Helleday, T., Helin, K., & Sørensen, C. S. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200706150 · Cited by 227
Self-citationSeiler, J. A., Conti, C., Syed, A., Aladjem, M. I., & Pommier, Y. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02278-06 · Cited by 226
Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Lin, L., Hoog, J., Goiffon, R. J., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 225
How dormant origins promote complete genome replication
Blow, J. J., Ge, X. Q., & Jackson, D. A. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.05.002 · Cited by 221
Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
COLLINS, I., & GARRETT, M. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.009 · Cited by 220
Deregulated Overexpression of hCdt1 and hCdc6 Promotes Malignant Behavior
Liontos, M., Koutsami, M., Sideridou, M., Evangelou, K., Kletsas, D., Levy, B., Kotsinas, A., Nahum, O., Zoumpourlis, V., Kouloukoussa, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2837 · Cited by 217
Ewald, B., Sampath, D., & Plunkett, W. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0633 · Cited by 216
Centore, R. C., Havens, C. G., Manning, A. L., Li, J.-M., Flynn, R. L., Tse, A., Jin, J., Dyson, N. J., Walter, J. C., & Zou, L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.015 · Cited by 216
Foote, K. M., Blades, K., Cronin, A., Fillery, S., Guichard, S. S., Hassall, L., Hickson, I., Jacq, X., Jewsbury, P. J., McGuire, T. M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301859s · Cited by 214
Wang, W.-J., Wu, S.-P., Liu, J.-B., Shi, Y.-S., Huang, X., Zhang, Q.-B., & Yao, K.-T. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1408 · Cited by 212
Sirbu, B. M., Couch, F. B., & Cortez, D. (2012) · Nature Protocols · doi:10.1038/nprot.2012.010 · Cited by 207
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Montagnoli, A., Valsasina, B., Croci, V., Menichincheri, M., Rainoldi, S., Marchesi, V., Tibolla, M., Tenca, P., Brotherton, D., Albanese, C., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.90 · Cited by 206
Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction
Gilmartin, A. G., Faitg, T. H., Richter, M., Groy, A., Seefeld, M. A., Darcy, M. G., Peng, X., Federowicz, K., Yang, J., Zhang, S.-Y., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1427 · Cited by 205
Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors
Carvajal, D., Tovar, C., Yang, H., Vu, B. T., Heimbrook, D. C., & Vassilev, L. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3576 · Cited by 201
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970
Hall, A. B., Newsome, D., Wang, Y., Boucher, D. M., Eustace, B., Gu, Y., Hare, B., Johnson, M. A., Li, H., Milton, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2158 · Cited by 199
Lee, J., Kumagai, A., & Dunphy, W. G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00045-5 · Cited by 198
Swe1Wee1-Dependent Tyrosine Phosphorylation of Hsp90 Regulates Distinct Facets of Chaperone Function
Mollapour, M., Tsutsumi, S., Donnelly, A. C., Beebe, K., Tokita, M. J., Lee, M.-J., Lee, S., Morra, G., Bourboulia, D., Scroggins, B. T., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.005 · Cited by 196
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.243 · Cited by 195
Skp2-dependent degradation of p27kip1 is essential for cell cycle progression
Kossatz, U., Dietrich, N., Zender, L., Buer, J., Manns, M. P., & Malek, N. P. (2004) · Genes & Development · doi:10.1101/gad.321004 · Cited by 194
Sausville, E., LoRusso, P., Carducci, M., Carter, J., Quinn, M. F., Malburg, L., Azad, N., Cosgrove, D., Knight, R., Barker, P., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192
Gray, D., Jubb, A. M., Hogue, D., Dowd, P., Kljavin, N., Yi, S., Bai, W., Frantz, G., Zhang, Z., Koeppen, H., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4531 · Cited by 190
MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
Nawrocki, S. T., Griffin, P., Kelly, K. R., & Carew, J. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707192 · Cited by 186
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185
RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells
Budke, B., Logan, H. L., Kalin, J. H., Zelivianskaia, A. S., Cameron McGuire, W., Miller, L. L., Stark, J. M., Kozikowski, A. P., Bishop, D. K., & Connell, P. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks353 · Cited by 185
Chk1 and p21 Cooperate to Prevent Apoptosis during DNA Replication Fork Stress
Rodriguez, R., & Meuth, M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-07-0594 · Cited by 182
Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR
Schoppy, D. W., Ragland, R. L., Gilad, O., Shastri, N., Peters, A. A., Murga, M., Fernandez-Capetillo, O., Diehl, J. A., & Brown, E. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58928 · Cited by 182
Petermann, E., Maya-Mendoza, A., Zachos, G., Gillespie, D. A. F., Jackson, D. A., & Caldecott, K. W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.3319-3326.2006 · Cited by 181
Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I–DNA complexes
Regairaz, M., Zhang, Y.-W., Fu, H., Agama, K. K., Tata, N., Agrawal, S., Aladjem, M. I., & Pommier, Y. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201104003 · Cited by 180
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins
Gong, Y., Zack, T. I., Morris, L. G. T., Lin, K., Hukkelhoven, E., Raheja, R., Tan, I.-L., Turcan, S., Veeriah, S., Meng, S., et al. (2014) · Nature Genetics · doi:10.1038/ng.2981 · Cited by 177
Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
Koniaras, K., Cuddihy, A. R., Christopoulos, H., Hogg, A., & O'Connell, M. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204942 · Cited by 176
Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Toledo, L. I., Murga, M., & Fernandez‐Capetillo, O. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.002 · Cited by 175
Cannell, I. G., Kong, Y. W., Johnston, S. J., Chen, M. L., Collins, H. M., Dobbyn, H. C., Elia, A., Kress, T. R., Dickens, M., Clemens, M. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910015107 · Cited by 172
Cited by
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Damia, G., & Broggini, M. (2019) · Cancers · doi:10.3390/cancers11010119 · Cited by 298
Metadata
- Authors
- Dobbelstein, M., & Sørensen, C. S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-05-08
- Volume
- 14
- Issue
- 6
- Pages
- 405-423
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1628408467
- Cited by
- 302
- References
- 298
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.